Among the drug resistance mechanisms in DHFR-targeted anti-cancer therapy, the best known is the amplification of the DHFR gene which leads to the increase in DHFR level after a prolonged methotrexate MTX treatment (Carman et al., 1984; Banerjee et al., 2002). This evidence concerns the gene DHFR and cancer.